EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of platensimycin, platencin, and platensilin overproducers by biosynthetic pathway engineering and fermentation medium optimization

Lucas L Fluegel iD, Ming-Rong Deng iD, Ping Su iD, Edward Kalkreuter iD, Dong Yang iD, Jeffrey D Rudolf iD, Liao-Bin Dong iD, Ben Shen iD

Journal of Industrial Microbiology and Biotechnology · 2024

DOI: 10.1093/jimb/kuae003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Industrial Microbiology and Biotechnology, 2024. Verfasst von Lucas L Fluegel und 7 weiteren Autor:innen. Beteiligte Einrichtung: D epartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458,…. Hauptthemen laut MEDLINE: Diterpenes, Biological Products, Aminophenols, Aminobenzoates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The platensimycin (PTM), platencin (PTN), and platensilin (PTL) family of natural products continues to inspire the discovery of new chemistry, enzymology, and medicine. Engineered production of this emerging family of natural products, however, remains laborious due to the lack of practical systems to manipulate their biosynthesis in the native-producing Streptomyces platensis species. Here we report solving this technology gap by implementing a CRISPR-Cas9 system in S. platensis CB00739 to develop an expedient method to manipulate the PTM, PTN, and PTL biosynthetic machinery in vivo. We showcase the utility of this technology by constructing designer recombinant strains S. platensis SB12051, SB12052, and SB12053, which, upon fermentation in the optimized PTM-MS medium, produced PTM, PTN, and PTL with the highest titers at 836 mg L−1, 791 mg L−1, and 40 mg L−1, respectively. Comparative analysis of these resultant recombinant strains also revealed distinct chemistries, catalyzed by PtmT1 and PtmT3, two diterpene synthases that nature has evolved for PTM, PTN, and PTL biosynthesis. The ΔptmR1/ΔptmT1/ΔptmT3 triple mutant strain S. platensis SB12054 could be envisaged as a platform strain to engineer diterpenoid biosynthesis by introducing varying ent-copalyl diphosphate-acting diterpene synthases, taking advantage of its clean metabolite background, ability to support diterpene biosynthesis in high titers, and the promiscuous tailoring biosynthetic machinery. One-Sentence Summary Implementation of a CRISPR-Cas9 system in Streptomyces platensis CB00739 enabled the construction of a suite of designer recombinant strains for the overproduction of platensimycin, platencin, and platensilin, discovery of new diterpene synthase chemistries, and development of platform strains for future diterpenoid biosynthesis engineering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiterpenesBiological ProductsAminophenolsAminobenzoatesPolycyclic CompoundsStreptomycesAdamantaneAnilidesFermentationBiosynthetic Pathways

Stichwörter der Autor:innen

BiosynthesisMedium optimizationPathway engineeringPlatencinPlatensilinPlatensimycin

Substanzen

platencinplatensimycinDiterpenesBiological ProductsAminophenolsAminobenzoatesPolycyclic CompoundsAdamantaneAnilides

Autor:innen und Institutionen

  • D epartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, USA.
  • Skaggs Graduate School of Chemical and Biological Sciences, Scripps Research, Jupiter, FL 33458, USA.
  • Natural Products Discovery Center, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, USA.
  • Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, USA.

ORCID-Profile: Lucas L Fluegel, Ming-Rong Deng, Ping Su, Edward Kalkreuter, Dong Yang, Jeffrey D Rudolf, Liao-Bin Dong, Ben Shen

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NIH
  • Guangdong Institute of Microbiology, Guangzhou, Guangdong

Zitieren

APA

Fluegel, L. L., Deng, M. R., Su, P., Kalkreuter, E., Yang, D., Rudolf, J. D., Dong, L. B., & Shen, B. (2024). Development of platensimycin, platencin, and platensilin overproducers by biosynthetic pathway engineering and fermentation medium optimization. Journal of Industrial Microbiology and Biotechnology. https://doi.org/10.1093/jimb/kuae003

Vancouver

Fluegel LL, Deng MR, Su P, Kalkreuter E, Yang D, Rudolf JD, et al. Development of platensimycin, platencin, and platensilin overproducers by biosynthetic pathway engineering and fermentation medium optimization. Journal of Industrial Microbiology and Biotechnology. 2024. doi:10.1093/jimb/kuae003

BibTeX
@article{Fluegel2024,
  author = {Fluegel, Lucas L and Deng, Ming-Rong and Su, Ping and Kalkreuter, Edward and Yang, Dong and Rudolf, Jeffrey D and Dong, Liao-Bin and Shen, Ben},
  title = {Development of platensimycin, platencin, and platensilin overproducers by biosynthetic pathway engineering and fermentation medium optimization},
  journal = {Journal of Industrial Microbiology and Biotechnology},
  year = {2024},
  doi = {10.1093/jimb/kuae003}
}
Kostenlos starten →